We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TPVG:NYSETriplePoint Venture Growth BDC Corp. Analysis

Data as of 2026-08-02 - not real-time

$4.52

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

TPVG is trading at $4.52, which sits below its 20‑day SMA of $4.63 and well under the 50‑day SMA of $5.00, indicating short‑term weakness, while the 200‑day SMA sits at $5.58, reinforcing a longer‑term bearish bias. The RSI of 40.7 suggests the stock is not yet oversold, and the MACD line is marginally above its signal, offering a faint bullish hint, but the overall trend remains bearish with decreasing volume and a 30‑day volatility of 34%. Market sentiment is at an "Extreme Greed" level (92.88 on the Fear & Greed Index), yet the stock faces a max drawdown of nearly 36% and a beta below 1, pointing to heightened downside risk in a choppy environment.
Fundamentally, the company’s PE of 4.3 versus an industry average of 18 signals a deep value appearance, complemented by a low price‑to‑book of 0.52, but the DCF‑derived fair value of $0.69 is dramatically below the market price, implying overvaluation. A dividend yield of 20.8% looks attractive, but a payout ratio of 96% on thin operating cash flow (‑$58.5M) and a debt‑to‑equity of 127 raise serious sustainability concerns. The balance sheet’s $446M debt versus $8.6M cash and modest free cash flow of $34M further underscore financial strain, making the dividend and valuation outlook precarious despite the high yield.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below key moving averages and bearish trend direction
  • DCF fair value far below market price indicating overvaluation
  • Unsustainable dividend payout amid negative operating cash flow

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Potential price correction narrowing valuation gap
  • High dividend yield may retain income‑focused investors
  • Volatility remains elevated, limiting upside confidence

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Exposure to venture‑stage growth sectors could improve earnings
  • Heavy leverage and debt‑to‑equity ratio pose ongoing balance‑sheet risk
  • Dividend sustainability concerns may erode total return over time

Key Metrics & Analysis

Financial Health

Revenue Growth1.40%
Profit Margin47.08%
P/E Ratio4.3
ROE12.23%
ROA5.57%
Debt/Equity127.12
P/B Ratio0.5
Op. Cash Flow$-58531000
Free Cash Flow$34.2M
Industry P/E18.0

Technical Analysis

TrendBearish
RSI40.7
Support$4.39
Resistance$4.95
MA 20$4.63
MA 50$5.00
MA 200$5.58
MACDBullish
VolumeDecreasing
Fear & Greed Index92.88

Valuation

Fair Value$0.69
Target Price$6.00
Upside/Downside32.74%
GradeOvervalued
TypeValue
Dividend Yield20.80%

Risk Assessment

Beta0.68
Volatility34.24%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.